Effectiveness of first-line ET plus CDK4/6i in patients with HR+/HER2− aBC worsens progressively with decreasing ERα expression, and PgR expression adds further prognostic discrimination, with low ERα and PgR expression identifying a subgroup of patients with particularly poor outcomes.
F. Ligorio, L. Provenzano, R. Caputo et al.· EClinicalMedicine· 0 citations
In health care, artificial intelligence (AI) is emerging as a powerful tool to improve the quality of care, support health care professionals, and build a more streamlined and efficient health care system while also enhancing the patient experience. In particular, integrating AI into clinical practice through an innova...
A. Toss, L. Bellardita, A. Botticelli et al.· ESMO Open· 0 citations
This large collection of MBC cfDNA data is envisioned as an invaluable resource for the design and planning of future clinical trials, and cfDNA testing is now recommended in multiple advanced malignancies, including eligibility assessment for clinical trials.
I. Leshchiner, A. Medford, J. Cha et al.· Nature Communications· 0 citations
Abstract Background Stage at diagnosis, histologic grade, and molecular subtypes are established prognostic indicators for women with breast cancer (BC), but their impact on population-based survival estimates is poorly documented. This study assessed long-term BC survival trends according to these factors. Methods We...
Fabiola Giudici, D. Serraino, F. Puglisi et al.· The Oncologist· 0 citations
Evidence supporting ctDNA for early response monitoring during neoadjuvant therapy, postoperative minimal residual disease detection, and longitudinal molecular surveillance is summarized and ctDNA‐guided therapeutic interception strategies and emerging multimodal cell‐free DNA approaches are discussed.
S. Di Cosimo, V. Appierto, C. Reduzzi et al.· Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
